Caris Life Sciences Inc - Class A risk profile
46 Elevated one input has moved against it
Measured 21 October 2026 from CAI's filed statements. Recomputed nightly.
46 (Elevated), driven by Concentration at 98, over 7 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 44 | Elevated | Volatile | One-year price volatility — 68.5% |
| Operating pressure | 0 | Contained | Stable | Costs outgrowing revenue — -82.4 percentage points |
| Cash conversion | 30 | Normal | Easing | Capital spending against operating cash — 0.20x |
| Leverage and coverage | 29 | Normal | Easing | Interest cover — 1.19x |
| Competitive position | 40 | Elevated | Stable | Operating-margin gap against peers — -2.0 percentage points |
| Concentration | 98 | Acute | Stable | Geographic concentration — 9,740 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Caris Life Sciences Inc - Class A